These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 35170528)

  • 1. Verification of hepatitis B-related hepatocellular carcinoma predictive models to evaluate the risk of HCC in patients with liver cirrhosis under antiviral treatment.
    Huang X; Wang H; Zhang W; Gu E
    Eur J Gastroenterol Hepatol; 2022 May; 34(5):546-552. PubMed ID: 35170528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
    Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
    Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy.
    Jiang XY; Huang B; Huang DP; Wei CS; Zhong WC; Peng DT; Huang FR; Tong GD
    World J Gastroenterol; 2021 Mar; 27(11):1101-1116. PubMed ID: 33776376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B.
    Papatheodoridis GV; Sypsa V; Dalekos GN; Yurdaydin C; Van Boemmel F; Buti M; Calleja JL; Chi H; Goulis J; Manolakopoulos S; Loglio A; Voulgaris T; Gatselis N; Keskin O; Veelken R; Lopez-Gomez M; Hansen BE; Savvidou S; Kourikou A; Vlachogiannakos J; Galanis K; Idilman R; Esteban R; Janssen HLA; Berg T; Lampertico P
    J Hepatol; 2020 Jun; 72(6):1088-1096. PubMed ID: 31981727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis.
    Jeon MY; Lee HW; Kim SU; Heo JY; Han S; Kim BK; Park JY; Kim DY; Ahn SH; Han KH
    Hepatol Int; 2017 May; 11(3):268-276. PubMed ID: 28224351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B.
    Choi WM; Kim GA; Choi J; Choi GH; Lee YB; Sinn DH; Lim YS
    Gut; 2024 Mar; 73(4):649-658. PubMed ID: 37813567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective viral suppression is necessary to reduce hepatocellular carcinoma development in cirrhotic patients with chronic hepatitis B: Results of a 10-year follow up.
    Zhang W; Wang X; Wang Y; Zhao X; Duan W; Wang Q; Wu X; Kong Y; Ma H; You H; Ou X; Jia J
    Medicine (Baltimore); 2017 Nov; 96(44):e8454. PubMed ID: 29095292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Risk analysis for hepatocellular carcinoma in patients with chronic hepatitis B-associated cirrhosis complicated by type 2 diabetes mellitus: a 5-year prospective cohort study].
    Tang C; Hu C; Zhou Y; Song Y; Li M; Liao M; Sun J; Zhong C; Zhou L; Lin Z; Zhou Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2021 Mar; 41(3):313-318. PubMed ID: 33849820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients.
    Kim JH; Ko SY; Choe WH; Kwon SY; Lee CH
    Clin Mol Hepatol; 2013 Sep; 19(3):273-9. PubMed ID: 24133665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HBcrAg Predicts Hepatocellular Carcinoma Development in Chronic B Hepatitis Related Liver Cirrhosis Patients Undergoing Long-Term Effective Anti-Viral.
    Chang KC; Lin MT; Wang JH; Hung CH; Chen CH; Chiu SY; Hu TH
    Viruses; 2022 Nov; 14(12):. PubMed ID: 36560675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease.
    Cho JY; Paik YH; Sohn W; Cho HC; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    Gut; 2014 Dec; 63(12):1943-50. PubMed ID: 24615378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients.
    Wu X; Xu X; Zhou J; Sun Y; Ding H; Xie W; Chen G; Ma A; Piao H; Wang B; Chen S; Meng T; Ou X; Yang HI; Jia J; Kong Y; You H
    Clin Mol Hepatol; 2023 Jul; 29(3):747-762. PubMed ID: 37165622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
    Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
    Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of liver-related events in patients with compensated HBV-induced cirrhosis receiving antiviral therapy.
    Wu X; Zhou J; Sun Y; Ding H; Chen G; Xie W; Piao H; Xu X; Jiang W; Ma H; Ma A; Chen Y; Xu M; Cheng J; Xu Y; Meng T; Wang B; Chen S; Shi Y; Kong Y; Ou X; You H; Jia J
    Hepatol Int; 2021 Feb; 15(1):82-92. PubMed ID: 33460002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy.
    Oh JH; Lee HW; Sinn DH; Park JY; Kim BK; Kim SU; Kim DY; Ahn SH; Kang W; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Paik YH
    Hepatol Int; 2021 Aug; 15(4):892-900. PubMed ID: 34260013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B.
    Sohn W; Cho JY; Kim JH; Lee JI; Kim HJ; Woo MA; Jung SH; Paik YH
    Clin Mol Hepatol; 2017 Jun; 23(2):170-178. PubMed ID: 28506056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Virologic Response to Treatment on Short- and Long-term Outcomes of Patients With Chronic Hepatitis B Virus Infection and Decompensated Cirrhosis.
    Jang JW; Choi JY; Kim YS; Yoo JJ; Woo HY; Choi SK; Jun CH; Lee CH; Sohn JH; Tak WY; Lee YR; Han KH
    Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1954-1963.e3. PubMed ID: 29753085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The risk of hepatocellular carcinoma within and beyond the first 5 years of entecavir in Korean patients with chronic hepatitis B.
    Kim BG; Park NH; Lee SB; Jeon S; Park JH; Jung SW; Jeong ID; Bang SJ; Shin JW
    Liver Int; 2018 Dec; 38(12):2269-2276. PubMed ID: 30052303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy.
    Kim JH; Kim YD; Lee M; Jun BG; Kim TS; Suk KT; Kang SH; Kim MY; Cheon GJ; Kim DJ; Baik SK; Choi DH
    J Hepatol; 2018 Nov; 69(5):1066-1073. PubMed ID: 30075230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher risk of hepatocellular carcinoma in chronic hepatitis B vs chronic hepatitis C after achievement of virologic response.
    Kim GA; Han S; Kim HD; An J; Lim YS
    J Viral Hepat; 2017 Nov; 24(11):990-997. PubMed ID: 28499070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.